clinical trial · NCT06082102
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.·phase3·recruiting·n = 324
Relapsed/Refractory Marginal Zone LymphomaOrelabrutinibRituximabLenalidomideRituximab
brief summary
Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma
started
Dec 19, 2023
primary completion
Aug 31, 2028
completion
Feb 25, 2030
last updated
Sep 15, 2025
official title
A Randomized, Controlled, Open-label, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Orelabrutinib Plus Rituximab Versus Lenalidomide Plus Rituximab in Relapsed/Refractory Marginal Zone Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol